Objective：To observe the efficacy and safety of Eribulin - based regimen in patients with HER2 negative metastatic breast cancer in the real world. Methods：We retrospectively analyzed clinical data of 60 patients with HER2 - negative metastatic breast cancer who received Eribulin-based therapy in Jiangsu Province Hospital between January 2020 and November 2021. Results： 30% of patients received Eribulin monotherapy while 70% of patients received Eribulin - based combination therapy. After a median follow-up of 5 months，the median progression-free survival(PFS)was 4.30 months(95%CI：3.86-5.69 months)，Median overall survival (OS)was not reached. The overall response rate(ORR)was 25.00%，and disease control rate(DCR)was 76.67%. Log-rank univariate analysis showed that there was a statistically significant difference between Eribulin monotherapy versus Eribulin-based combination regimen(2.93 months vs. 4.7 months，P=0.042). Multivariate analysis indicated that age and chemotherapy lines were independent risk factors for PFS in patients with HER2- negative metastatic breast cancer treated with Eribulin(P=0.022，0.048). The most common grade Ⅲ-Ⅳ adverse events(AE)associated with Eribulin include neutropenia，leukopenia，anemia，and lymphopenia，and no treatment- related severe adverse event(SAE)or deaths were observed. Conclusion：Our research indicated that Eribulin - based regimen can effectively treat HER2-negative metastatic breast cancer with controllable side effects.